JPRN-UMIN000007007
Completed
未知
A randomized controlled trial of Attention Bias Modification Treatment (ABMT) for highly anxious adults: A functional MRI investigation of the neural mechanisms of the ABMT - A randomized controlled trial of Attention Bias Modification Treatment (ABMT) for highly anxious adults
ConditionsAnxiety
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Anxiety
- Sponsor
- Kitasato University
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Presence of significant psychiatric disorders determined by the Mini International Neuropsychiatric Interview 2\) Presence of significant medical illnesses 3\) History of traumatic brain injury 4\) Patient of psychiatry 5\) Psychotropic medication within the previous month 6\) Over\-intake of caffeine 7\) Metal implants that interfere with the MRI safety 8\) Pregnancy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy.Treatment of patients with primary dyslipidaemiaMedDRA version: 8Level: ptClassification code 10058108EUCTR2005-002316-24-DETakeda Europe R &D Centre Ltd400
Active, not recruiting
Phase 1
A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy.treatment of patients with primary dyslipidaemiaMedDRA version: 8Level: ptClassification code 10058108EUCTR2005-002316-24-SKTakeda Global R &D Centre (Europe)400
Active, not recruiting
Not Applicable
A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy.treatment of patients with primary dyslipidaemiaMedDRA version: 8Level: ptClassification code 10058108EUCTR2005-002316-24-LVTakeda Europe R &D Centre Ltd400
Active, not recruiting
Not Applicable
A study to see how effective and safe the drug Kappaproct is in patients with refractory ulcerative colitis when added to their standard care of treatmentChronic active treatment refractory ulcerative colitisMedDRA version: 16.1Level: PTClassification code 10009900Term: Colitis ulcerativeSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2011-003130-14-CZInDex Pharmaceuticals AB120
Active, not recruiting
Not Applicable
Clinical Trial to assess the efficacy and safety of KappaproctChronic active treatment refractory ulcerative colitisMedDRA version: 14.1Level: PTClassification code 10009900Term: Colitis ulcerativeSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2011-003130-14-ITINDEX PHARMACEUTICALS132